Summary
Eli Lilly and Company (LLY) held its 2025 Annual Meeting of Shareholders on May 5, 2025, with a strong turnout of approximately 89% of outstanding shares represented. The meeting's primary focus was on voting matters, including the election of directors, advisory approval of executive compensation, and ratification of the independent auditor. All management-proposed items, such as the election of the four director nominees and the ratification of Ernst & Young LLP as the independent auditor, received overwhelming support from shareholders, indicating strong confidence in the company's leadership and governance. However, two significant shareholder proposals to amend the company's Articles of Incorporation – one to eliminate the classified board structure and another to eliminate supermajority voting provisions – failed to receive the required 80% of outstanding shares for approval. While a majority of votes cast were in favor of these changes, the high threshold for approval was not met. This outcome suggests that while a portion of shareholders desire more immediate board changes and simplified voting, the current board structure and voting requirements remain in place, supported by a significant majority.
Key Highlights
- 1Four director nominees were overwhelmingly elected to serve three-year terms.
- 2Shareholders provided advisory approval for the compensation of named executive officers with strong support.
- 3Ernst & Young LLP was ratified as the Company's independent auditor for 2025 with substantial shareholder approval.
- 4A proposal to eliminate the classified board structure did not pass, failing to meet the required 80% of outstanding shares.
- 5A proposal to eliminate supermajority voting provisions also failed to achieve the necessary 80% of outstanding shares for approval.
- 6A high voter turnout of approximately 89% of outstanding shares was achieved at the annual meeting.